Industry-sponsored satellite symposia at the 23rd EURETINA Congress

News
Article

Attendees can take advantage of many satellite symposia, sponsored by industry and feauring experts from around the world

A bridge and bicycles in Amsterdam. Image credit: ©andreykr – stock.adobe.com

During the EURETINA congress, there will be 1-hour symposia sessions on Thursday, Friday and Saturday. Image credit: ©andreykr – stock.adobe.com

The 23rd annual EURETINA Congress will be held from October 5 to October 7 in Amsterdam, the Netherlands. The venue is RAI Amsterdam.

In addition to the numerous educational opportunities offered by the Congress program, attendees also can take advantage of many satellite symposia sponsored by industry. Experts from around the world will present during the symposia.

The following are the titles of the 1-hour symposia sessions. All times listed are expressed in Central European Summer Time (CEST).

Thursday October 5

  • 13:30 – 14:30 CEST: Change in treatment paradigm for DME with faricimab: Evidence from clinical trials and real-world practice (sponsored by Roche)

Friday October 6

  • 09:45 - 10:45 CEST: Eye to Eye - Maximize your surgical approach (sponsored by Alcon)
  • 09:45 - 10:45 CEST: Current management of inherited retinal diseases: the X-linked retinitis pigmentosa perspective (sponsored by Janssen)
  • 09:45 - 10:45 CEST: Have we maximised patient outcomes, or can we go further? (sponsored by Bayer)
  • 13:45 - 14:45 CEST: Modern imaging and algorithms for interrogating chorioretinal disease (sponsored by Nidek)
  • 13:45 - 14:45 CEST: Exploring diabetic macular edema: clinical considerations and perspectives on its management (sponsored by Novartis)
  • 13:45 - 14:45 CEST: Informed decision-making every step of the way - PART 1 : Diagnostic imaging in disease management (sponsored by Zeiss)
  • 13:45 - 14:45 CEST: Change in treatment paradigm for nAMD with faricimab: Evidence from clinical trials and real-world practice (sponsored by Roche)
  • 13:45 - 14:45 CEST: Advances in ultra-widefield multimodal retinal imaging - learn from our experts (sponsored by Optos)
  • 17.45 - 18.45 CEST: The future of continuous drug delivery for retinal diseases (sponsored by Roche)

Saturday October 7

  • 10:15 - 11:15 CEST: Is sustained disease control the new benchmark for patient care? (sponsored by Bayer)
  • 10:15 - 11:15 CEST: Laser for retina and vitreous: All you need to know in 2023 (sponsored by Lumibird)
  • 10:15 - 11:15 CEST: Informed decision-making every step of the way - Part 2: Visualization in vitreoretinal surgery (sponsored by Zeiss)
  • 10:15 - 11:15 CEST: Discovering ChANGe with Ang-2 (sponsored by Roche)
  • 10:15 - 11:15 CEST: IME: Dry AMD & GA IME Platform: practical considerations for GA treatment (sponsored by the Euretina Education Platform)
  • 13:00 - 14:00 CEST: Geographic atrophy: navigating to the future (sponsored by Apellis)
  • 13:00 - 14:00 CEST: What is Bayer’s vision for the future of ophthalmology? (sponsored by Bayer)
  • 13:00 - 14:00 CEST: New dimensions in visualization: changing the way you look (sponsored by Bausch & Lomb)
  • 13:00 - 14:00 CEST: High-resolution OCT in retinal disorders including atrophic AMD (sponsored by Heidelberg Engineering)
  • 13:00 - 14:00 CEST: LIGHTSITE III pivotal trial 24-month analysis: multiwavelength Valeda® Light Delivery System Treatment in early/intermediate dry age-related macular degeneration patients(sponsored by LumiThera)
  • 18:00 - 19:00 CEST: Retinale® - EURETINA Kompakt (sponsored by Roche)
Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.